S&P 500   4,269.22 (-0.44%)
DOW   33,326.65 (-0.54%)
QQQ   359.69 (+0.40%)
AAPL   173.60 (+1.40%)
MSFT   320.05 (+1.36%)
META   305.32 (+1.70%)
GOOGL   133.62 (+2.11%)
AMZN   129.54 (+1.90%)
TSLA   249.68 (-0.22%)
NVDA   445.68 (+2.46%)
NIO   8.79 (-2.77%)
BABA   86.29 (-0.52%)
AMD   102.41 (-0.40%)
T   14.72 (-2.00%)
F   12.30 (-0.97%)
MU   67.74 (-0.43%)
CGC   0.74 (-5.61%)
GE   108.89 (-1.50%)
DIS   81.54 (+0.60%)
AMC   8.08 (+1.13%)
PFE   33.79 (+1.87%)
PYPL   58.80 (+0.58%)
NFLX   380.13 (+0.67%)
S&P 500   4,269.22 (-0.44%)
DOW   33,326.65 (-0.54%)
QQQ   359.69 (+0.40%)
AAPL   173.60 (+1.40%)
MSFT   320.05 (+1.36%)
META   305.32 (+1.70%)
GOOGL   133.62 (+2.11%)
AMZN   129.54 (+1.90%)
TSLA   249.68 (-0.22%)
NVDA   445.68 (+2.46%)
NIO   8.79 (-2.77%)
BABA   86.29 (-0.52%)
AMD   102.41 (-0.40%)
T   14.72 (-2.00%)
F   12.30 (-0.97%)
MU   67.74 (-0.43%)
CGC   0.74 (-5.61%)
GE   108.89 (-1.50%)
DIS   81.54 (+0.60%)
AMC   8.08 (+1.13%)
PFE   33.79 (+1.87%)
PYPL   58.80 (+0.58%)
NFLX   380.13 (+0.67%)
S&P 500   4,269.22 (-0.44%)
DOW   33,326.65 (-0.54%)
QQQ   359.69 (+0.40%)
AAPL   173.60 (+1.40%)
MSFT   320.05 (+1.36%)
META   305.32 (+1.70%)
GOOGL   133.62 (+2.11%)
AMZN   129.54 (+1.90%)
TSLA   249.68 (-0.22%)
NVDA   445.68 (+2.46%)
NIO   8.79 (-2.77%)
BABA   86.29 (-0.52%)
AMD   102.41 (-0.40%)
T   14.72 (-2.00%)
F   12.30 (-0.97%)
MU   67.74 (-0.43%)
CGC   0.74 (-5.61%)
GE   108.89 (-1.50%)
DIS   81.54 (+0.60%)
AMC   8.08 (+1.13%)
PFE   33.79 (+1.87%)
PYPL   58.80 (+0.58%)
NFLX   380.13 (+0.67%)
S&P 500   4,269.22 (-0.44%)
DOW   33,326.65 (-0.54%)
QQQ   359.69 (+0.40%)
AAPL   173.60 (+1.40%)
MSFT   320.05 (+1.36%)
META   305.32 (+1.70%)
GOOGL   133.62 (+2.11%)
AMZN   129.54 (+1.90%)
TSLA   249.68 (-0.22%)
NVDA   445.68 (+2.46%)
NIO   8.79 (-2.77%)
BABA   86.29 (-0.52%)
AMD   102.41 (-0.40%)
T   14.72 (-2.00%)
F   12.30 (-0.97%)
MU   67.74 (-0.43%)
CGC   0.74 (-5.61%)
GE   108.89 (-1.50%)
DIS   81.54 (+0.60%)
AMC   8.08 (+1.13%)
PFE   33.79 (+1.87%)
PYPL   58.80 (+0.58%)
NFLX   380.13 (+0.67%)
NASDAQ:APVO

Aptevo Therapeutics (APVO) Stock Forecast, Price & News

$0.33
0.00 (-0.09%)
(As of 02:10 PM ET)
Compare
Today's Range
$0.32
$0.34
50-Day Range
$0.31
$1.14
52-Week Range
$0.30
$7.20
Volume
211,517 shs
Average Volume
153,321 shs
Market Capitalization
$3.80 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

Aptevo Therapeutics MarketRank™ Forecast

Analyst Rating
N/A
Upside/​Downside
N/A
Short Interest
Healthy
0.40% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.72mentions of Aptevo Therapeutics in the last 14 days
Based on 5 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($2.37) to ($2.26) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.69 out of 5 stars


APVO stock logo

About Aptevo Therapeutics (NASDAQ:APVO) Stock

Aptevo Therapeutics Inc., a clinical-stage biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. The company's lead clinical candidates are APVO436, a bispecific T-cell engaging antibody candidate that is in Phase 1b clinical trial for acute myelogenous leukemia and myelodysplastic syndromes; and. ALG.APV-527, an investigational bispecific ADAPTIR candidate that features a mechanism of action to target 4-1BB (CD137) and 5T4, a tumor antigen expressed in various types of cancers. Its preclinical candidates include APVO603, a dual agonist bispecific antibody to target 4-1BB and OX40; APVO711, a dual mechanism bispecific ADAPTIR candidate designed to provide synergistic stimulation of CD40 on antigen presenting cells; and APVO442, a bispecific candidate based on the ADAPTIR-FLEX platform technology to enhance biodistribution of drugs to PSMA positive tumors for treatment of prostate cancer. The company has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527. Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.

APVO Price History

APVO Stock News Headlines

Better Than Oil Stocks
The best way to profit from energy is NOT a stock...Rather, it's this little-known alternative investment. 
Aptevo Therapeutics Inc
This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
APVO - Aptevo Therapeutics Inc.
Short Volatility Alert: Aptevo Therapeutic
See More Headlines
Receive APVO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aptevo Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

APVO Company Calendar

Last Earnings
8/10/2023
Today
10/02/2023
Next Earnings (Estimated)
11/09/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:APVO
Employees
45
Year Founded
2016

Profitability

Net Income
$8.03 million
Pretax Margin
225.24%

Debt

Sales & Book Value

Annual Sales
$3.11 million
Book Value
$2.78 per share

Miscellaneous

Free Float
11,098,000
Market Cap
$3.80 million
Optionable
Optionable
Beta
5.24

Social Links

7 Stocks to Buy And Hold Forever Cover

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Key Executives

  • Mr. Marvin L. White (Age 61)
    Pres, CEO & Director
    Comp: $892.86k
  • Mr. Jeffrey G. Lamothe CA (Age 57)
    Exec. VP & COO
    Comp: $691.37k
  • Ms. SoYoung Kwon J.D.
    LL.M., Sr. VP, Gen. Counsel, Bus. Devel. & Corp. Affairs
  • Ms. Daphne L. Taylor (Age 57)
    Sr. VP & CFO
  • Dr. Jane A. Gross Ph.D. (Age 66)
    Chief Scientific Officer
  • Dr. Fatih M. Uckun M.D.
    Ph.D., Chief Clinical Advisor & Consultant
  • Dr. Dirk Huebner M.D. (Age 60)
    Chief Medical Officer













APVO Stock - Frequently Asked Questions

How have APVO shares performed in 2023?

Aptevo Therapeutics' stock was trading at $2.32 at the beginning of 2023. Since then, APVO stock has decreased by 85.8% and is now trading at $0.33.
View the best growth stocks for 2023 here
.

Are investors shorting Aptevo Therapeutics?

Aptevo Therapeutics saw a drop in short interest in the month of September. As of September 15th, there was short interest totaling 46,000 shares, a drop of 46.6% from the August 31st total of 86,200 shares. Based on an average daily volume of 319,700 shares, the short-interest ratio is currently 0.1 days.
View Aptevo Therapeutics' Short Interest
.

When is Aptevo Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 9th 2023.
View our APVO earnings forecast
.

How were Aptevo Therapeutics' earnings last quarter?

Aptevo Therapeutics Inc. (NASDAQ:APVO) announced its quarterly earnings data on Thursday, August, 10th. The biotechnology company reported ($1.23) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.12) by $0.11.

What other stocks do shareholders of Aptevo Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Aptevo Therapeutics investors own include Advanced Micro Devices (AMD), Amarin (AMRN), AVEO Pharmaceuticals (AVEO), Alibaba Group (BABA), Micron Technology (MU), OPKO Health (OPK), AbbVie (ABBV), Aurinia Pharmaceuticals (AUPH), BioXcel Therapeutics (BTAI) and T2 Biosystems (TTOO).

What is Aptevo Therapeutics' stock symbol?

Aptevo Therapeutics trades on the NASDAQ under the ticker symbol "APVO."

How do I buy shares of Aptevo Therapeutics?

Shares of APVO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Aptevo Therapeutics' stock price today?

One share of APVO stock can currently be purchased for approximately $0.33.

How much money does Aptevo Therapeutics make?

Aptevo Therapeutics (NASDAQ:APVO) has a market capitalization of $3.80 million and generates $3.11 million in revenue each year.

How can I contact Aptevo Therapeutics?

Aptevo Therapeutics' mailing address is 2401 4TH AVENUE SUITE 1050, SEATTLE WA, 98121. The official website for the company is www.aptevotherapeutics.com. The biotechnology company can be reached via phone at (206) 838-0500, via email at jurchisons@apvo.com, or via fax at 206-838-0503.

This page (NASDAQ:APVO) was last updated on 10/2/2023 by MarketBeat.com Staff

My Account -